BHI Weekly Newsletter Archives

Pete Briskman, an Executive Managing Director with JLL, leads the Tenant Advisory and brokerage business for JLL in Maryland, sits down with BioTalk Host Rich Bendis to talk his role with JLL, his focus on Life Sciences, and vision of the BioHealth Capital Region

Pete Briskman works with many of the regions’ most exciting and fastest growing Life Science Companies assisting them with their real estate and site selection strategies for Headquarter transactions, relocations, build-to-suits, renewals, expansions, and consolidations. Pete and his team bring proprietary tools to help organizations make informed decisions around the size and scale of their operation, assessment of labor, modeling and programming of occupancy, approach to optimizing business and economic incentives, and very unique real estate market intelligence that can be communicated via our proprietary geo-spatial market intelligence platform.  He is the recipient of GWCAR’s Commercial Leasing Broker of the Year and has been recognized with GWCAR Office Leasing Transactions of the Year for multiple clients.

Read More

New Members to Add Experience to Board of Directors

ROCKVILLE, MARYLAND, February 12, 2020 – BioHealth Innovation, Inc. (BHI) announced that its Board of Directors unanimously has approved the appointments of six new board members:

• Sean Augerson, Vice President, Head of Operations Americas and APAC, QIAGEN
• Peter Briskman, Executive Managing Director, JLL
• Juergen Klenk, Ph.D., Principal, Deloitte
• Dr. Jay Perman, MD, Chancellor, University System of Maryland
• Aaron Ren, Head of Business Development and Operations, Viela Bio
• Tracey Vetterick, Vice President and COO, Oncology R&D, AstraZeneca

“I am privileged to welcome these new members to our board,” said Richard Bendis, BHI President and CEO. “The addition of their leadership experience in the BioHealth Capital Region and beyond ensures in BHI’s ability to have our finger on the pulse of innovation and fresh viewpoints. I also would like to thank Rip Ballou of GSK, Robert Caret of the University System of Maryland, Doug Liu of QIAGEN, Ashish Kulkarni, of Avantor, and Beth Meagher of Deloitte Consulting LLP for their many years of service on our Board of Directors.

Read More

With the coronavirus growing more deadly each day, several companies are racing to produce the first vaccine or antiviral medication to combat the spread of the virus. One company that seems to have made large strides towards finding a vaccine, is Gaithersburg-based Novavax.

The genome of the coronavirus was published last month, which opened the floodgates for potential vaccine attempts. Novavax is most notable for releasing an Ebola vaccine within 90 days of the genome being published in 2015, and they estimate they could have a similar timetable for this vaccine as well.

Read More

New Enterprise Associates Partner Sara Nayeem sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York.

The venture capital fund, which has a cumulative committed capital of $20 billion, focuses on investing in across all verticals in healthcare and in technology.

Image: https://www.proactiveinvestors.com

Read More

APPLY NOW 

Gain Visibility for Your BioHealth Company – and $10,000.

Prior winners:  Sonavex, LifeSprout, Galen Robotics, Floreo 

Read More

BALTIMORE, February 18, 2020 (Newswire.com) – Over 40 million patient records were breached in 2019, according to new data released today in the Protenus Breach Barometer®. Published by Protenus, a healthcare compliance analytics platform that protects patient data for the nation’s leading health systems, the Breach Barometer is the industry’s definitive source for health data breach reporting.  

Read More

SANTA MONICA, Calif.–(BUSINESS WIRE)–Feb. 10, 2020– Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Read More

The NIA Office of Small Business Research (OSBR) team is intrigued by startups and their unique role in research and development. Of course, we’re a bit biased — after all, we lead NIA’s Small Business Innovation Research (SBIR) and Small Business Technology Transfer Research (STTR) programs, which are designed to help new companies commercialize products and technology to extend the healthy, active years of life.

Read More

The University System of Maryland Maryland Momentum Fund and the University of Maryland, Baltimore, have invested $350,000 in a medical technology startup, the 11th investment from the fund. University of Maryland BioPark startup ARMR Systems Inc. was awarded $350,000, the first time a BioPark resident has received an investment from the fund. The university investments led ARMR’s …

Read More

Mtech Ventures, a University of Maryland technology company incubator program, won a $50,000 U.S. Small Business Administration Growth Accelerator Fund competition award to support innovation in federal Opportunity Zones in the Baltimore-Washington metropolitan area.

Through the grant, Mtech Ventures is partnering with the Association of University Research Parks (AURP) and the Center for Accelerating Innovation to organize community-needs roundtables, identify promising innovations, develop entrepreneurs and build awareness of Small Business Innovation Research (SBIR) or Small Business Tech Transfer (STTR) program in low-income census tracts called federal Opportunity Zones (OZ). Maryland has 149 Opportunity Zones, while the District of Columbia has 25. Federal tax incentives for new investments are available in these zones.

Read More

Citizens across Virginia need health solutions and affordable health care to live full, healthy and productive lives. Lawmakers in the General Assembly are examining a broad range of policies in an attempt to relieve the burden of rising health care costs. But some of the proposals under consideration might have unintended consequences for both patients and Virginia’s innovation economy. As our elected officials consider how to address health care costs, they should ensure that any measure provides meaningful financial relief to patients and preserves the environment for medical innovation in Virginia that delivers groundbreaking treatments and creates thousands of high-paying jobs in the commonwealth.

Image: Kelli Price Photography

Read More

WASHINGTON – The National Capital Consortium for Pediatric Device Innovation (NCC-PDI) announced today that the application deadline for its annual “Make Your Medical Device Pitch for Kids!” competition is extended one week to Feb. 22 at midnight EST. Innovators and startup companies with devices in the pediatric cardiovascular, orthopedic and spine, or NICU sectors are invited to apply for a share of up to $250,000 in FDA-funded awards and access to a newly created NCC-PDI pediatric device accelerator program led by MedTech Innovator. Applications are being accepted now.

Read More

HHS on Monday launched a new program to spur development and commercialization of technologies that would help the U.S. respond to health security threats and disasters.

The Foundry for American Biotechnology, a public-private partnership, will be jointly managed by the department’s Office of the Assistant Secretary for Preparedness and Response—or ASPR—and the New Hampshire technology firm Deka Research and Development Corp.

Read More

Two commercial real estate firms with a significant presence in the marketing of life sciences properties have issued reports over the past 12 months that illustrate the growth in industry employment in recent years.

One life sciences segment, “Research and Development in Biotechnology” (NAICS code 541714), has largely driven that growth, with its number of jobs more than doubling over the past decade, to 204,800 as of 2019, according to the U.S. Bureau of Labor Statistics (BLS) data cited by Cushman & Wakefield in “Life Sciences 2020: The Future Is Here,” a report released February 6. Between 2010 and 2019, biotech R&D employment grew 5.1%, compared with 1.6% for total employment. Most of the increase, more than 70,000 jobs, occurred between 2013 and 2019.

Read More

The University of Maryland announced Wednesday that it has appointed a new president.

The University System of Maryland Board of Regents appointed Darryll J. Pines to succeed Wallace Loh. Pines’ appointment is effective July 1, and he will be the 34th president of the University of Maryland, College Park.

Pines has been the A. James Clark School of Engineering dean for the past 11 years. He has been with the university for 25 years, starting as an assistant professor in 1995.

Image: https://umdrightnow.umd.edu/news/usm-board-regents-appoints-darryll-j-pines-president-university-maryland-college-park

Read More

Representatives of various industries trekked to Annapolis for a marathon hearing on several bills aimed at generating revenue for public education reforms.

Image: Representatives from the Maryland Department of Commerce said getting rid tax credit programs would send a signal that the state is not committed to growing businesses and supporting economic development. BBJ FILE

Read More

ROCKVILLE, Md., Feb. 11, 2020 /PRNewswire/ — The Institute for Bioscience and Biotechnology Research (IBBR) is accepting proposals to lease a bio-manufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, pre-clinical manufacturing for material necessary to conduct IND-enabling toxicology studies, proof of concept (POC) studies, and process demonstration in advance of Good Manufacturing Practices (GMP) manufacturing. IBBR is a joint research enterprise between the University of Maryland and the National Institute of Standards and Technology (NIST).

Image: https://finance.yahoo.com

Read More

NEW BRUNSWICK, N.J., February 11, 2020 – Johnson & Johnson today announced that its Janssen Pharmaceutical Companies will further expedite its investigational coronavirus vaccine program through an expanded collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services.

Image: https://www.jnj.com

Read More

Rebecca Stauffer, Parenteral Drug Association Managing Editor posed the following questions to PDA Letter Article readers in fall of 2019. “What if developers of cell and gene therapies treated their products like software releases? What if the human body could be manipulated like a highly complex computer?”

We invite you to join us for a LIVE and interactive presentation from Jeff Galvin, CEO of American Gene Technologies sharing his passion, vision, and conviction of “reprogramming the human computer.”

Image: https://www.eventbrite.com

Read More

FREDERICK, Md.–(BUSINESS WIRE)–The Maryland Tech Council (MTC) announced today it has expanded its offices to Frederick to broaden its reach throughout the State of Maryland and to meet the growing needs of its members. The satellite office will be located at 12 West Church Street. Additionally, MTC is planning a move of its Montgomery County satellite office to the Universities at Shady Grove (USG) in Rockville. MTC will continue to utilize its satellite offices in Annapolis and other key life science and tech hubs throughout Maryland.

Read More

Feb. 10, 2020 — Linda Larrimore has been getting chemotherapy every other week for 6 years to treat and manage colon cancer.

The chemotherapy is keeping her health stable, so it’s well worth it to the mother and grandmother to regularly get the treatment. Usually, she spends the 4½ hours every other week reading, watching TV, or chatting.

Image: https://www.webmd.com

Read More

Here’s a useful article that looks at the fate of university-licensed startup (ULS) life sciencecompanies over the last few years. There are more and more such companies (a greater than tenfold increase in their number since 1990), but a comprehensive look at success rates (and how such rates vary according to the universities involved) has been harder to come by. A lot of work went into this overview, and I’m glad the authors were able to assemble it. They spent a lot of time digging through tech-transfer records and contacting universities to make sure that they’d covered everything, checking venture capital announcements and state corporate registrations, and searching through press releases, LinkedIn pages, and more. The data that they have produced look like the best we have on the subject.

Read More

The streets of Wuhan, China — the epicenter of the coronavirus outbreak — are empty and quiet except for the sound of loudspeakers squawking quarantine instructions to its sheltered-in-place residents. Flights to some Chinese cities have been terminated. A Tokyo, Japan-based travel agency has canceled nearly 20,000 of its Chinese package tours.

The World Health Organization (WHO) has declared the coronavirus, which has already killed more people than SARS, a global health emergency. There are currently 11 people stricken with the novel virus in the U.S. and over 17,000 are infected globally with numbers jumping exponentially by the day.

Image: https://biobuzz.io

Read More

I made illustration of Corona virus today.

Read More

The first BioTalk of 2020 kicks off with Andrea Alms, MS, MBA, Co-Fund Manager of BioHealth Capital Fund as she discusses her background, the world of Angel Investment, and her vision for the Fund

Click here to listen to the podcast.

Andrea Alms is the co-fund manager of BioHealth Capital Fund.  The BioHealth Capital Fund is a venture capital early stage investment fund created by the BioHealth Innovation (“BHI”), located in Rockville, MD, the center of the BioHealth Capital Region. BHI manages a for profit subsidiary BioHealth Innovation Management (BHIM) which owns equity in 27 of the 108 client companies of BHI and has had 3 exits. Our lead investor is Alexandria Real Estate Equities; and, our reference is Joel Marcus.  Andrea is recognized for her abilities in guiding venture capital, private equity, mergers and acquisitions (M&A), and other transactions involving early stage companies. Andrea assists limited partners, general partners, investors, and entrepreneurs as they create, build, and buy or sell businesses, primarily in BioHealth, healthcare, technology, and digital health products industries.

Read More

Here’s a list of our upcoming events.  Get them on your calendar so you don’t miss anything.

Click here for the full list

Read More

SOMERSET, N.J. & GOSSELIES, Belgium–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, and MaSTherCell Global, Inc., a technology-focused cell and gene therapy contract development and manufacturing organization to leading cell therapy innovators, today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. (NASDAQ:ORGS), for an aggregate of $315 million in cash, subject to a customary adjustments.

Read More

As it gears up for expansion in 2020, Baltimore-based Avhana Health is kicking off a partnership with one of Florida’s largest health system, cofounder Noah Weiner said.

The downtown Baltimore-based company is working with AdventHealth to launch its platform that improves electronic health records throughout the system’s network of doctor’s offices.

Image: Avhana Health cofounders and brothers Noah and Nate Weiner. (Courtesy photo)

Read More

BHI is assisting one of its client companies, Medimaps) seeking US sales, customer and marketing support (see position descriptions). Medimaps is an exciting start-up company that is prepared to grow exponentially in the next phase and is looking for dynamic, experienced, and flexible people interested in being a part of this journey. The company is seeking someone who would like to be a critical player to the success of this exciting medtech company. Medimaps Group (MG) is the leader in bone and tissue microarchitecture software analytics. Its proven technology helps doctors make improved clinical decisions for the patients. Over the past several years, Medimaps has developed innovative technology, demonstrated and published clinical efficacy, received regulatory approval, built its network of distributors and partners around the world, and gained worldwide acceptance as standards of care for osteoporosis fracture risk assessment. Medimaps’ premier product, Trabecular Bone Score (TBS) is sold in more than 60 countries. MG currently has 20+ employees between our Headquarters in Geneva Switzerland, our R&D in Bordeaux, France, and our General Office in the US which is expanding. To apply for either position, please send your resume, cover letter, and three professional references to BHI@BIoHealthInnovation.org

Read More

Montgomery College’s Workforce Development and Continuing Education (WDCE) Program will offer a program for budding entrepreneurs in Montgomery County to gain start-up business resources and get newly created businesses registered. The program, named LaunchCamp, starts April 7 and is a 12-week sprint for entrepreneurial-minded students to turn their ideas into registered businesses with identified customers.

Funded through the Montgomery College Foundation Innovation Fund, this start-up business accelerator is an easy-to-apply program that requires just a 1-page business plan, called the Lean Canvas.

Read More

Now that we have stepped over the threshold into 2020, what has the research community learned that will propel progress and how can we enable changes that can move health and science forward?

Here’s a look a 10 trends and big ideas we are watching as this new decade unfolds:

1. Making patients the priority: Retail, banking, and other consumer-focused industries have placed the consumer in the center.

Read More

George Mason University is now looking for private partners to help it build its Amazon-inspired expansion of its Arlington campus, outlining preliminary plans for a building with 225,000 square feet of academic space and 135,000 square feet of private office and retail.

University officials released a request for proposals Tuesday, looking for developers interested in teaming up with Mason to build a new home for the Institute of Digital Innovation on its Virginia Square property. The building is set to include a mix of uses across its 460,000 square feet, with room for classes and research labs alongside space for companies big and small looking to partner with the university.

Image: https://www.bizjournals.com

Read More

BALTIMORE, United States of America, February 6, 2020/APO Group/ — Hemafuse, a surgical autotransfusion device, will revolutionize blood access across Africa. Hemafuse is designed to salvage and recycle whole blood from cases of internal bleeding. The device can be used in both emergencies and scheduled procedures to recover blood from where it pools inside of a patient, into a blood bag, where it is immediately available to be re-transfused back to that same patient.

Read More

CNBC’s Meg Tirrell reports on testing efforts here in the U.S. to detect the coronavirus. With Qiagen’s interim CEO, Thierry Bernard, in Boston.

Read More

Developing medication, devices, and products for children is not a matter of “shrinking” down the adult version. Delivering solutions to our littlest patients requires a long-term approach that deliberately centers children in all stages of innovation – from ideation to incubation, from clinical trials to market.

 Join Chief Innovation Officer of Children’s National Health System Kolaleh Eskandanian and experts in pediatric medical device innovation for a candid discussion on the challenges and opportunities upon designing innovation with children in mind.

Read More

Herndon, VA, Feb. 04, 2020 (GLOBE NEWSWIRE) — The Center for Innovative Technology (CIT) today announced the appointment of Greg Feldmann, President of Skyline Capital Strategies, an affiliate of Woods Rogers, PLC, as CIT GAP Funds Venture Partner. CIT GAP Funds and affiliated Virginia Founder’s Fund (VFF) are committed to identifying viable start-up investment opportunities in all parts of the Commonwealth. As a Venture Partner, Feldmann will provide outreach services to cultivate new and existing sources of deal flow and early-stage investment capital in the Roanoke-Blacksburg corridor, Southside Virginia, Lynchburg and Far Southwest Virginia.“CIT recognizes the wealth of technology and strong entrepreneurial spirit of the Roanoke-Blacksburg corridor and adjacent geographies,” said Tom Weithman, Managing Director of CIT GAP Funds. “A critical part of harnessing those assets to create economic development benefit for the Commonwealth turns on mobilizing capital to drive development of emerging companies.

Image: https://www.streetinsider.com

Read More

In June 2019, MLP Ventures’ The Discovery Labs announced renovation plans for GlaxoSmithKline’s R&D space in King of Prussia, Pennsylvania it acquired the previous year for about $50 million with the goal of turning the space into “co-working” ecosystem for healthcare, life sciences and technology-enabled companies.

Read More

Merck & Co. Inc. unveiled plans Wednesday to spin off products from its women’s health and biosimilars businesses, along with certain legacy brands, into a new independent and publicly traded company.

Going forward, Merck (NYSE: MRK) will focus on its oncology, vaccines, hospital medicine and animal health segments.

Merck expects the spinoff to be completed by the first half of 2021. The pharmaceutical giant anticipates cost savings of more than $1.5 billion — primarily in areas such as manufacturing and sales staff costs — by 2024. In addition, Merck said by continuing to increase investments in its key growth drivers and pipeline assets, it is targeting operating margins to grow to more than 40% in 2024.

Read More

Its potential 1.7 million-square-foot campus in South San Francisco matches the biotech industry’s growth.

Read More

Startup Maryland recently unveiled video pitches from the participants in the 2019 STRT1UP Roadshow. Entrants are now in the running for the Pitch Across Maryland competition. Categories this year for the Pitch Across Maryland include: Fan Favorite, Champions’ Choice, Industries and Overall Winner.

The STRT1UP Roadshow, which is the year-long tour around the state, involves the video bus into which entrepreneurs climb to deliver a two to four minute video pitch summarizing their venture and opportunity, according to a Startup Maryland press release.

Read More

Life sciences and biotechnology business ventures in Southeastern North Carolina could get a boost through a new competition launched Tuesday by the N.C. Biotechnology Center Southeastern Office, in partnership with UNCW’s CIE.

Entrepreneurs and companies can now apply for the NC BIONEER Venture Challenge, which aims to “raise the profile, increase the volume, and enhance the success of life science commercialization, entrepreneurs, and companies in the region,” according to the venture challenge website.

Read More

Register now for the eighth annual Public Health Research at Maryland day on Tuesday April 7. We’ll delve into the latest research focused on improving the health and well-being of diverse communities across Maryland, the nation and the world. This year’s theme, Our 2020 Vision for Healthy People 2030, highlights the release of the new Healthy People Objectives for 2030 on March 31.

Read More

Vigene Biosciences Inc.’s has opened its new research facility in Rockville.

The opening of a new laboratory at 5 Research Court — near Interstate-270’s Shady Grove Road exit — significantly increases the biotech’s Rockville footprint, adding 51,000 square feet to its existing 20,000 square feet at a separate facility nearby. The project cost more than $20 million, according to Vigene.

Read More

Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced the company has been awarded a Small Business Innovation Research (SBIR) Phase II grant by the National Institutes of Health (NIH) in the amount of $3.9 million to support development of TLY012 for treatment of chronic pancreatitis.

Read More

Benjamin Wu, the new CEO and president of the Montgomery County Economic Development Corp., is quickly building out his staff.

The former top adviser to Maryland Gov. Larry Hogan has brought on five new hires since stepping in to lead Montgomery’s economic development efforts on Dec. 18, including a new senior vice president for business development and an opportunity zones project leader.

Read More

February is Rare Disease Awareness Month, a month-long celebration focused on the suffering and triumphs of patients and their families stricken by rare diseases culminating on February 29th – International Rare Disease Day. The rapidly developing cell and gene therapy fields in recent years have led to a rare disease R&D boom of sorts, with an estimated 800 rare disease-focused clinical development projects currently in process. The biotech industry sees a new window for improving rare disease patient’s lives and potentially curing rare diseases that impact one in ten American and an estimated 400 million people globally.

Image: https://biobuzz.ios

Read More

GlaxoSmithKline has licensed a tuberculosis vaccine to the Bill & Melinda Gates Medical Research Institute (MRI). The deal sets the stage for a push to build on recent phase 2b data and make the vaccine available in low-income countries where TB is prevalent.

The vaccine, M72/AS01E, is made up of an immunogenic fusion protein based on two TB antigens. GSK combined that protein with the adjuvant found in its shingles prophylactic Shingrix to create a subunit vaccine. Last year, a phase 2b trial linked the vaccine to 50% protection against progression to active pulmonary tuberculosis for three years in adults infected with the mycobacterium.

Image: Bill Gates (CC BY 2.0/Ben Fisher/GAVI Alliance)

Read More

Developing medication, devices, and products for children is not a matter of “shrinking” down the adult version. Delivering solutions to our littlest patients requires a long-term approach that deliberately centers children in all stages of innovation – from ideation to incubation, from clinical trials to market.

Read More

Here’s a list of our upcoming events.  Get them on your calendar so you don’t miss anything.

Click here for the full list

Read More

Boston Properties has entered into a joint venture with Alexandria Real Estate Equities to build a 1.7M SF life science campus in South San Francisco.

Boston Properties confirmed the deal in its Q4 2019 earnings call this week.

The project will involve about 640K SF of ground-up development, and the potential repositioning of about 1M SF of office space into new life science buildings, according to Boston Properties.

Image: Wikimedia Commons/Coolcaesar at the English language Wikipedia

Read More

The Johns Hopkins Center for Systems Science and Engineering has built and is regularly updating an online dashboard for tracking the worldwide spread of the coronavirus outbreak that began in the Chinese city of Wuhan.

Lauren Gardner, a civil engineering professor and CSSE’s co-director, spearheaded the effort to launch the mapping website on Wednesday. The site displays statistics about deaths and confirmed cases of coronavirus, or 2019-nCoV, across a worldwide map. It also allows visitors to download the data for free.

Image: https://hub.jhu.edu

Read More

What Nobel Laureate Dr. Jim Allison’s Story Can Teach Entrepreneurs and Innovators

Jim Allison shared the Nobel Prize in Physiology or Medicine in 2018, along with Tasuku Hanjo, for pioneering the use of immune checkpoint inhibitors to develop cancer therapies.

Allison’s remarkable and groundbreaking research into T-Cell activation, and his subsequent work developing his discoveries into viable cancer treatment, has extended the lives of thousands of cancer patients. Allison’s work is more than remarkable: It represents an earth-shaking paradigm shift in scientific thought about how cancer works and could be defeated.

Read More

Around the world, populations are getting older, and their health needs are becoming more complex. At the same time, technological advances are changing healthcare delivery. In this edition, The Next Normal explores how hospitals will innovate in the coming decade—and what it will mean for both patients and healthcare professionals.

Read More

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

Read More

“The Best Networking Event in the MidAtlantic.” This will be our 43rd consecutive Sold Out event over the last 9 years! Over 70% of previous attendees surveyed say that CONNECTpreneur is the “Number One” tech and investor event in the Mid-Atlantic region! This unique event is like none other in the Mid-Atlantic, because of the high quality of our attendees, speakers and presenters. And YES, the networking is unprecedented!

Read More

BHI is seeking a full time energetic and motivated individual with relevant marketing experience and an interest in growing with our organization to serve as our full time Marketing and Communications Coordinator. The Marketing and Communications Coordinator will perform a variety of duties that support the organization’s mission, including formulating and executing a strategic marketing plan for the organization that encompasses BHI’s goals for the next three years and providing ongoing marketing collateral creation and marketing administrative support.

Click here for more information.

Read More

Qiagen NV shares jumped the most in 17 years after people with knowledge of the matter said Thermo Fisher Scientific Inc. is considering a takeover of the molecular testing firm.

Thermo Fisher has approached the Dutch company about a potential purchase that could become one of its biggest-ever acquisitions, the people said, asking not to be identified because the information is private. Shares of Qiagen rose 13% to 33.20 euros at 1:10 p.m. in Frankfurt, giving it a market value of $8.3 billion.

Read More

Virginia Tech is coming to Children’s National Hospital’s new campus at the former Walter Reed Army Medical Center.

The partnership will bring a 12,000-square-foot biomedical research complex to the 12-acre Children’s National Research and Innovation Campus, slated to deliver in December 2020 as part of the project’s first phase. In the university’s first D.C. location, Virginia Tech’s Fralin Biomedical Research Institute at Virginia Tech Carilion will establish a D.C. team to work with Children’s National on translational research projects, faculty recruiting, intellectual property work and commercialization, and trainings for students and fellows — all focused on pediatric cancers of the brain and nervous system.

Read More

Earlier this year we reported on the First of Its Kind Apprenticeship Program at GSK’s Rockville, Maryland Site. We are happy to provide an update on that story with news that GlaxoSmithKline (GSK) has expanded their apprenticeship program to now include Biopharmaceutical Associates.

GSK is an industry-leading pharmaceutical, consumer products and healthcare company and is known for taking a future-oriented approach to their talent strategies. The Validation Technician Apprenticeship was the first of its kind in the U.S. pharmaceutical industry. They have also begun to explore Virtual Reality training as a model that can be used to speed up employee development.

Read More

Antimicrobial resistance (AMR) is in the news lately and for good reason. Diseases that were once easy to treat are becoming increasingly difficult to cure. But the largest contributor to AMR is a disease that rarely makes headlines – drug-resistant tuberculosis (DR-TB), the world’s only airborne drug-resistant infection. DR-TB makes up a third of the world’s burden of AMR and in 2017, there were more than half a million cases of DR-TB globally [1] – including some right here in the District of Columbia. It is estimated that two-thirds of individuals with DR-TB do not even know they are infected [2], posing a threat to their own health and to global health security.

Read More

Newswise — If the saying that two heads are better than one is true, then joining two fields of science may be better than one to spur more advances in medicine. With a $6.7 million, five-year grant from the National Institutes of Health, Johns Hopkins Medicine researchers will bring together immunologists, oncologists and biomedical engineers in an effort to build new tools to treat cancer and autoimmune diseases.

Read More

One company gets absorbed into a larger brand and a host of companies flower as a result. The Biohealth Capital Region’s (BHCR) cycle of creative destruction has continued with Harpoon Medical. This was the story shared at the TEDCO Entrepreneur Expo’s session titled, “Success Breeds Success.”

Image: https://biobuzz.io

Read More

Leeds, UK, 14 November 2019: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, today announced it has spun out of the University of Leeds with £2.65M funding in the first close of a Series A financing round. The investment is being led by Epidarex Capital and the University of Leeds. The Company was founded based on IP generated by Prof Helen Philippou and Dr Richard Foster, through unique insights built on a decade of academic research into Factor XII which has been supported by the Wellcome Trust, British Heart Foundation and the Medical Research Council.

Read More

Johns Hopkins University has become the first university in the world to partner with Innovation for Defense, the North Atlantic Treaty Organization Innovation Hub’s new initiative. Also called I4D, the Norfolk, Virginia–based center aims to bring together a variety of partners to design solutions to challenges the organization faces.

Read More

November 14, 2019, Baltimore, MD – Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the appointment of Todd Chappell, a veteran medtech and pharmaceutical industry executive, as the company’s CEO.

Read More

Join the world’s largest multi-sector technology commercialization program. The Innovation Showcase offers a unique and vetted pipeline for corporate, federal and VC prospectors to discover and connect with emerging technologies.

Read More

ROCHESTER, N.Y., Nov. 08, 2019 (GLOBE NEWSWIRE) — Empire State Development (ESD) announced the 10 companies selected to take part in the Round III of New York State’s Luminate NY accelerator competition in Rochester. The finalists selected include optics, photonics and imaging startups which were selected after pitching their innovative ideas to an advisory panel comprised of industry experts during the Lightning Awards at the Strong National Museum of Play on Nov. 7. Each company will receive an initial investment of $100,000 and will be a part of Luminate’s third cohort, which will begin in January 2020 at the Sibley Building in downtown Rochester. The six-month program will help the selected companies speed the commercialization of their technologies and business. In June, the teams will compete during Demo Day for $2 million in follow-on funding. Funding for the $25 million program is being provided through the Finger Lakes Forward Upstate Revitalization Initiative award and is being administered by NextCorps.

Read More

FRANKFURT, Nov 18 (Reuters) – Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors.

Germany-listed shares in the company were up 12.6% at 0926 GMT, giving the group an equity market value of about 8.7 billion euros ($9.6 billion).

Read More

BHI is seeking a full time energetic and motivated individual with relevant marketing experience and an interest in growing with our organization to serve as our full time Marketing and Communications Coordinator. The Marketing and Communications Coordinator will perform a variety of duties that support the organization’s mission, including formulating and executing a strategic marketing plan for the organization that encompasses BHI’s goals for the next three years and providing ongoing marketing collateral creation and marketing administrative support.

Click here for more information.

Read More

Qiagen NV shares jumped the most in 17 years after people with knowledge of the matter said Thermo Fisher Scientific Inc. is considering a takeover of the molecular testing firm.

Thermo Fisher has approached the Dutch company about a potential purchase that could become one of its biggest-ever acquisitions, the people said, asking not to be identified because the information is private. Shares of Qiagen rose 13% to 33.20 euros at 1:10 p.m. in Frankfurt, giving it a market value of $8.3 billion.

Read More

Virginia Tech is coming to Children’s National Hospital’s new campus at the former Walter Reed Army Medical Center.

The partnership will bring a 12,000-square-foot biomedical research complex to the 12-acre Children’s National Research and Innovation Campus, slated to deliver in December 2020 as part of the project’s first phase. In the university’s first D.C. location, Virginia Tech’s Fralin Biomedical Research Institute at Virginia Tech Carilion will establish a D.C. team to work with Children’s National on translational research projects, faculty recruiting, intellectual property work and commercialization, and trainings for students and fellows — all focused on pediatric cancers of the brain and nervous system.

Read More

Earlier this year we reported on the First of Its Kind Apprenticeship Program at GSK’s Rockville, Maryland Site. We are happy to provide an update on that story with news that GlaxoSmithKline (GSK) has expanded their apprenticeship program to now include Biopharmaceutical Associates.

GSK is an industry-leading pharmaceutical, consumer products and healthcare company and is known for taking a future-oriented approach to their talent strategies. The Validation Technician Apprenticeship was the first of its kind in the U.S. pharmaceutical industry. They have also begun to explore Virtual Reality training as a model that can be used to speed up employee development.

Read More

Antimicrobial resistance (AMR) is in the news lately and for good reason. Diseases that were once easy to treat are becoming increasingly difficult to cure. But the largest contributor to AMR is a disease that rarely makes headlines – drug-resistant tuberculosis (DR-TB), the world’s only airborne drug-resistant infection. DR-TB makes up a third of the world’s burden of AMR and in 2017, there were more than half a million cases of DR-TB globally [1] – including some right here in the District of Columbia. It is estimated that two-thirds of individuals with DR-TB do not even know they are infected [2], posing a threat to their own health and to global health security.

Read More

Newswise — If the saying that two heads are better than one is true, then joining two fields of science may be better than one to spur more advances in medicine. With a $6.7 million, five-year grant from the National Institutes of Health, Johns Hopkins Medicine researchers will bring together immunologists, oncologists and biomedical engineers in an effort to build new tools to treat cancer and autoimmune diseases.

Read More

One company gets absorbed into a larger brand and a host of companies flower as a result. The Biohealth Capital Region’s (BHCR) cycle of creative destruction has continued with Harpoon Medical. This was the story shared at the TEDCO Entrepreneur Expo’s session titled, “Success Breeds Success.”

Image: https://biobuzz.io

Read More

Leeds, UK, 14 November 2019: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, today announced it has spun out of the University of Leeds with £2.65M funding in the first close of a Series A financing round. The investment is being led by Epidarex Capital and the University of Leeds. The Company was founded based on IP generated by Prof Helen Philippou and Dr Richard Foster, through unique insights built on a decade of academic research into Factor XII which has been supported by the Wellcome Trust, British Heart Foundation and the Medical Research Council.

Read More

Johns Hopkins University has become the first university in the world to partner with Innovation for Defense, the North Atlantic Treaty Organization Innovation Hub’s new initiative. Also called I4D, the Norfolk, Virginia–based center aims to bring together a variety of partners to design solutions to challenges the organization faces.

Read More

November 14, 2019, Baltimore, MD – Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the appointment of Todd Chappell, a veteran medtech and pharmaceutical industry executive, as the company’s CEO.

Read More

Join the world’s largest multi-sector technology commercialization program. The Innovation Showcase offers a unique and vetted pipeline for corporate, federal and VC prospectors to discover and connect with emerging technologies.

Read More

ROCHESTER, N.Y., Nov. 08, 2019 (GLOBE NEWSWIRE) — Empire State Development (ESD) announced the 10 companies selected to take part in the Round III of New York State’s Luminate NY accelerator competition in Rochester. The finalists selected include optics, photonics and imaging startups which were selected after pitching their innovative ideas to an advisory panel comprised of industry experts during the Lightning Awards at the Strong National Museum of Play on Nov. 7. Each company will receive an initial investment of $100,000 and will be a part of Luminate’s third cohort, which will begin in January 2020 at the Sibley Building in downtown Rochester. The six-month program will help the selected companies speed the commercialization of their technologies and business. In June, the teams will compete during Demo Day for $2 million in follow-on funding. Funding for the $25 million program is being provided through the Finger Lakes Forward Upstate Revitalization Initiative award and is being administered by NextCorps.

Read More

FRANKFURT, Nov 18 (Reuters) – Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors.

Germany-listed shares in the company were up 12.6% at 0926 GMT, giving the group an equity market value of about 8.7 billion euros ($9.6 billion).

Read More

BHI is seeking a full time energetic and motivated individual with relevant marketing experience and an interest in growing with our organization to serve as our full time Marketing and Communications Coordinator. The Marketing and Communications Coordinator will perform a variety of duties that support the organization’s mission, including formulating and executing a strategic marketing plan for the organization that encompasses BHI’s goals for the next three years and providing ongoing marketing collateral creation and marketing administrative support.

Click here for more information.

Read More

Qiagen NV shares jumped the most in 17 years after people with knowledge of the matter said Thermo Fisher Scientific Inc. is considering a takeover of the molecular testing firm.

Thermo Fisher has approached the Dutch company about a potential purchase that could become one of its biggest-ever acquisitions, the people said, asking not to be identified because the information is private. Shares of Qiagen rose 13% to 33.20 euros at 1:10 p.m. in Frankfurt, giving it a market value of $8.3 billion.

Read More

Virginia Tech is coming to Children’s National Hospital’s new campus at the former Walter Reed Army Medical Center.

The partnership will bring a 12,000-square-foot biomedical research complex to the 12-acre Children’s National Research and Innovation Campus, slated to deliver in December 2020 as part of the project’s first phase. In the university’s first D.C. location, Virginia Tech’s Fralin Biomedical Research Institute at Virginia Tech Carilion will establish a D.C. team to work with Children’s National on translational research projects, faculty recruiting, intellectual property work and commercialization, and trainings for students and fellows — all focused on pediatric cancers of the brain and nervous system.

Read More

Earlier this year we reported on the First of Its Kind Apprenticeship Program at GSK’s Rockville, Maryland Site. We are happy to provide an update on that story with news that GlaxoSmithKline (GSK) has expanded their apprenticeship program to now include Biopharmaceutical Associates.

GSK is an industry-leading pharmaceutical, consumer products and healthcare company and is known for taking a future-oriented approach to their talent strategies. The Validation Technician Apprenticeship was the first of its kind in the U.S. pharmaceutical industry. They have also begun to explore Virtual Reality training as a model that can be used to speed up employee development.

Read More

Antimicrobial resistance (AMR) is in the news lately and for good reason. Diseases that were once easy to treat are becoming increasingly difficult to cure. But the largest contributor to AMR is a disease that rarely makes headlines – drug-resistant tuberculosis (DR-TB), the world’s only airborne drug-resistant infection. DR-TB makes up a third of the world’s burden of AMR and in 2017, there were more than half a million cases of DR-TB globally [1] – including some right here in the District of Columbia. It is estimated that two-thirds of individuals with DR-TB do not even know they are infected [2], posing a threat to their own health and to global health security.

Read More

Newswise — If the saying that two heads are better than one is true, then joining two fields of science may be better than one to spur more advances in medicine. With a $6.7 million, five-year grant from the National Institutes of Health, Johns Hopkins Medicine researchers will bring together immunologists, oncologists and biomedical engineers in an effort to build new tools to treat cancer and autoimmune diseases.

Read More

One company gets absorbed into a larger brand and a host of companies flower as a result. The Biohealth Capital Region’s (BHCR) cycle of creative destruction has continued with Harpoon Medical. This was the story shared at the TEDCO Entrepreneur Expo’s session titled, “Success Breeds Success.”

Image: https://biobuzz.io

Read More

Leeds, UK, 14 November 2019: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, today announced it has spun out of the University of Leeds with £2.65M funding in the first close of a Series A financing round. The investment is being led by Epidarex Capital and the University of Leeds. The Company was founded based on IP generated by Prof Helen Philippou and Dr Richard Foster, through unique insights built on a decade of academic research into Factor XII which has been supported by the Wellcome Trust, British Heart Foundation and the Medical Research Council.

Read More

Johns Hopkins University has become the first university in the world to partner with Innovation for Defense, the North Atlantic Treaty Organization Innovation Hub’s new initiative. Also called I4D, the Norfolk, Virginia–based center aims to bring together a variety of partners to design solutions to challenges the organization faces.

Read More

November 14, 2019, Baltimore, MD – Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the appointment of Todd Chappell, a veteran medtech and pharmaceutical industry executive, as the company’s CEO.

Read More

Join the world’s largest multi-sector technology commercialization program. The Innovation Showcase offers a unique and vetted pipeline for corporate, federal and VC prospectors to discover and connect with emerging technologies.

Read More

ROCHESTER, N.Y., Nov. 08, 2019 (GLOBE NEWSWIRE) — Empire State Development (ESD) announced the 10 companies selected to take part in the Round III of New York State’s Luminate NY accelerator competition in Rochester. The finalists selected include optics, photonics and imaging startups which were selected after pitching their innovative ideas to an advisory panel comprised of industry experts during the Lightning Awards at the Strong National Museum of Play on Nov. 7. Each company will receive an initial investment of $100,000 and will be a part of Luminate’s third cohort, which will begin in January 2020 at the Sibley Building in downtown Rochester. The six-month program will help the selected companies speed the commercialization of their technologies and business. In June, the teams will compete during Demo Day for $2 million in follow-on funding. Funding for the $25 million program is being provided through the Finger Lakes Forward Upstate Revitalization Initiative award and is being administered by NextCorps.

Read More

FRANKFURT, Nov 18 (Reuters) – Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors.

Germany-listed shares in the company were up 12.6% at 0926 GMT, giving the group an equity market value of about 8.7 billion euros ($9.6 billion).

Read More

Gaithersburg’s Viela Bio Inc. began publicly trading Thursday on the Nasdaq.

The clinical-stage biotech is offering 7.9 million shares of common stock priced at $19 per share, positioning the company to raise roughly $150 million. Viela (NASDAQ: VIE) is also giving underwriters the option to buy up to an additional 1.19 million shares at the initial public offering price for 30 days.

Image: Viela Bio CEO Bing Yao and colleagues rang the opening Nasdaq bell Thursday. LIBBY GREENE

Read More

GAITHERSBURG, Md., Oct. 03, 2019 (GLOBE NEWSWIRE) — Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to advance the Company’s ARC-T + sparX programs, including clinical development of a bivalent BCMA-targeted cell therapy in multiple myeloma, and a CD123-targeted therapy in acute myeloid leukemia. The Series B will also fund earlier stage ARC-T + sparX programs for patients with solid tumors and diseases outside oncology.

Read More

The ribbon was cut today at GSK’s recently expanded manufacturing facility in Rockville, marking the completion of a $139M project that was first announced in May 2017 to support growing demand for BENLYSTA® (belimumab), a treatment for adult patients with Lupus.

Image: https://biobuzz-io.cdn.ampproject.org

Read More

Gregg L. Semenza, whose discoveries on how cells respond to low oxygen levels have the potential to result in treatments for a variety of illnesses, today was awarded the 2019 Nobel Prize in Physiology or Medicine by the Nobel Assembly at the Karolinska Institutet in Stockholm.

The academy recognized Semenza, the C. Michael Armstrong Professor of Medicine at the Johns Hopkins University School of Medicine, for his groundbreaking discovery of hypoxia-inducible factor 1, or HIF-1, the protein that switches genes on and off in cells in response to low oxygen levels.

Image: https://hub.jhu.edu

Read More

GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately $7 million in proceeds. Investors include Alexandria Venture Investments as well as a large integrated healthcare delivery network currently exploring the option to implement PhageBank™ therapy within its network of more than 17 hospitals and a NYSE-listed specialty life sciences company. Proceeds will be deployed to support multi-center phase 2 clinical studies for its PhageBank® therapy for antibiotic resistant bacterial infections.

Image: https://biobuzz.io

Read More

New Enterprise Associates Partner, Sara Nayeem, M.D., Joins Host Rich Bendis to Discuss Her Career, Venture Capital, and BioPharma

Sara Nayeem, M.D., is a Partner at New Enterprise Associates (NEA). Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Centrexion, Complexa, Cydan, Imara, and Tiburio. She previously served on the boards of Vtesse (acquired by Sucampo), Mersana (MRSN) and Therachon and as a board observer for Loxo Oncology (LOXO, acquired by Lilly), Tesaro (TSRO, acquired by GlaxoSmithKline), Clementia (CMTA, acquired by Ipsen), Nightstar (NITE, acquired by Biogen), Ziarco (acquired by Novartis), Omthera (OMTH, acquired by AstraZeneca), Epizyme (EPZM), Millendo (MLND) and Zyngenia. She has also been involved in other NEA investments such as Prosensa (RNA, acquired by BioMarin), Metacrine, and 3-V Biosciences. She also serves on the board of BioHealth Innovation Management. Prior to joining NEA, Sara was an Associate with Merrill Lynch’s Global Healthcare Group, where she advised biotechnology, pharmaceutical and medical device companies on numerous mergers, acquisitions and financing transactions. Previously, she worked as an Investment Banking Analyst at Morgan Stanley. She has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. Sara concurrently earned her MD (cum laude) and MBA from Yale University, where she was a Yale MBA Scholar. She received her AB (magna cum laude) in Biology from Harvard University.

Listen now on iTunes (https://apple.co/2o1V6Il), Google Podcasts (http://bit.ly/2oGqQ6h), and TuneIn (http://bit.ly/2ndZGmO).

Read More

The second annual BHCR Investment Conference, which is an invitation-only event, will be held at AstraZeneca in Gaithersburg on October 15 and 16, 2019.

BioHealth Innovation (BHI), J.P. Morgan, Wilson Sonsini Goodrich & Rosati (WSGR), Deloitte, AstraZeneca and The Maryland Department of Commerce have worked closely to ensure the 2019 investment conference builds on the success of last year’s event.

Image: https://biobuzz.io

Read More

CAMBRIDGE, Mass. and GAITHERSBURG, Md., Oct. 07, 2019 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell medicines, including EDIT-301, an experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia.

Read More

Leiden, Utrecht October 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to market organoid models on a Chip. The agreement includes a license to MIMETAS to market HUB Organoids in an assay ready format, as well as a collaborative effort to develop disease-specific models.

Read More

Happening now at the #BioInnovationConference, Henry Ahn of National Science Foundation (NSF), Joseph Naft of #MIPS, Judy Costello of BioHealth Innovation, Inc. , Paul Silber of Blu Ventures #Investors, & Jeff Galvin of American Gene Technologies International Inc. discuss “Alternative Funding Options for Launching Your Company.”

AGT will do our best to share resources mentioned during this talk after the conference for startups and early-stage companies.

Read More

The National Institute on Drug Abuse (NIDA) awarded Emergent BioSolutions a $6.3 million research grant for further development of the company’s treatment for opioid addiction.

Specifically, the funding is for the continued development of AP007, Emergent’s sustained-release nalmefene formulation for the treatment of addiction in opioid use disorder (OUD). AP007 is designed to continually release an effective dose of nalmefene for up to three months and to be administered through intramuscular injection.

Read More